ADC Biotechnology
Antibody-drug conjugate development and bioconjugation process technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| GBP | 2015 | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | (2 %) | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (158 %) | (274 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (171 %) | (337 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
ADC Biotechnology, founded in 2010 and headquartered in Saint Asaph, United Kingdom, operates as a contract development and manufacturing organization (CDMO) specializing in antibody-drug conjugates (ADCs) for the oncology market. The company provides bioconjugation development services and process technology to assist drug developers in the production of ADC-based anti-cancer therapies.
A core component of the company's offering is its proprietary 'Lock-Release' technology. This patented system is designed to create a more efficient, simplified, and cost-effective manufacturing process for ADCs by immobilizing proteins on solid supports during conjugation. This method aims to reduce production complexity, shorten development timelines by up to three months, and enhance product quality by minimizing aggregate formation and residual free drugs.
In December 2020, Sterling Pharma Solutions announced a strategic partnership and significant investment in ADC Biotechnology, with the intent to acquire the company. The acquisition was finalized in April 2021, and ADC Biotechnology's facility in Deeside, Wales, was rebranded as part of Sterling's international network. The merger created an integrated service combining Sterling's expertise in cGMP manufacturing and high-potency active pharmaceutical ingredients (APIs) with ADC Bio's specialization in bioconjugation, establishing a center of excellence for ADC development.
Keywords: antibody-drug conjugate, bioconjugation, oncology, CDMO, process technology, Lock-Release technology, anti-cancer drugs, drug development, cGMP manufacturing, high potency API, contract manufacturing, cytotoxin, drug-linker synthesis, targeted therapy, pharmaceutical services